title: [Tacrine: progress in treatment of Alzheimer's disease?].
abstract: The cholinesterase inhibitor tacrine exerts a marked therapeutic effect only at a dose which is not tolerated by many patients because of the gastrointestinal side effects and hepatotoxicity of the drug. In patients who tolerate a high dose of tacrine the mean increase in cognitive abilities is roughly equivalent to the decline which occurs within 1 year in an untreated group. At a high dose tacrine may also temporarily delay the progression of symptoms of Alzheimer's disease. Only a minority of patients with mild to moderate Alzheimer's disease can be treated with tacrine. For them, however, tacrine is the most promising treatment option presently available.
authors.affiliation: Psychiatrische Klinik, Technischen Universität, München.
authors.forename: A
authors.initials: A
authors.lastname: Kurz
authors.forename: R
authors.initials: R
authors.lastname: Marquard
authors.forename: D
authors.initials: D
authors.lastname: Mösch
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000145:classification / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008134:Long-Term Care; D009483:Neuropsychological Tests; D013619:Tacrine / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D013619:Tacrine
vernacular_title: Tacrin: Ein Fortschritt in der Behandlung der Alzheimer-Krankheit?